April 11, 2024
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
April 3, 2024
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
March 8, 2024
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
February 22, 2024
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
February 8, 2024
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
January 8, 2024
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
January 3, 2024
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
December 12, 2023
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
November 29, 2023
Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
November 28, 2023
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND
Displaying 31 - 40 of 154